In June, the FDA gave the green light to the controversial Alzheimer’s drug Aduhelm from Biogen, although an advisory committee had previously spoken out against it.
(Photo: AP)
Bangalore According to a media report, the South Korean conglomerate Samsung Group is considering a multi-billion dollar takeover of the US biotech company Biogen. As the newspaper “Korea Economic Daily” reported on Wednesday, citing banking circles, Biogen could be valued at around 42 billion dollars in a transaction.
According to Refinitive data, Biogen is currently worth $ 34.67 billion. Samsung did not initially receive a comment, and Biogen declined to comment. On the US technology exchange Nasdaq, Biogen shares jumped eleven percent after the report in late trading.
In June, the FDA gave the green light to the controversial Alzheimer’s drug Aduhelm from Biogen, although an advisory committee had previously spoken out against it. The Alzheimer’s drug business has been sluggish since then.
The Samsung Group announced in August that it would invest almost $ 206 billion over the next three years. The money is to flow into the areas of biopharmaceuticals, artificial intelligence, semiconductors and the robot industry. According to the information at the time, the investments should help to strengthen the global position in key industries such as the chip sector and to boost growth in the post-corona period.
Top jobs of the day
Find the best jobs now and
be notified by email.
More: Doubts about effectiveness and criticism of the high price weigh on the launch of Biogen’s Alzheimer’s drug